Literature DB >> 12093915

Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution.

Hamid Echchakir1, Guillaume Dorothée, Isabelle Vergnon, Jeanne Menez, Salem Chouaib, Fathia Mami-Chouaib.   

Abstract

We have previously identified an antigen (Ag) recognized on a human large cell carcinoma of the lung by a tumor-specific cytotoxic T lymphocyte clone derived from autologous tumor infiltrating lymphocytes (TILs). The antigenic peptide is presented by HLA-A2 molecules and is encoded by a mutated alpha-actinin-4 (ACTN4) gene. In the present report, we have isolated two anti-alpha-actinin-4 T cell clones from the same patient TIL and from his peripheral blood lymphocytes (PBLs) by using tetramers of soluble HLA-A2 molecules loaded with the mutated peptide. Although all of the clones displayed similar tetramer labeling, those isolated from PBL showed lower avidity of Ag recognition and killed the specific target much less efficiently, indicating that tetramer staining does not correlate with clone avidity/tumor reactivity. T cell receptor (TCR) analysis revealed that alpha-actinin-4-reactive clones used distinct alpha and beta chain rearrangements, demonstrating TCR repertoire diversity. Interestingly, TCR beta chain gene usage indicated that only Ag-specific clones with high functional avidity were expanded at the tumor site, whereas a low-avidity clone was exclusively amplified in patient peripheral blood. Our results point to the existence of distinct but overlapping antitumor TCR repertoires in TIL and PBL and suggest a selective in situ expansion of tumor-specific cytotoxic T lymphocyte with high avidity/tumor reactivity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093915      PMCID: PMC123145          DOI: 10.1073/pnas.142308199

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  The human non-muscle alpha-actinin protein encoded by the ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells.

Authors:  S N Nikolopoulos; B A Spengler; K Kisselbach; A E Evans; J L Biedler; R A Ross
Journal:  Oncogene       Date:  2000-01-20       Impact factor: 9.867

2.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.

Authors:  M Marchand; N van Baren; P Weynants; V Brichard; B Dréno; M H Tessier; E Rankin; G Parmiani; F Arienti; Y Humblet; A Bourlond; R Vanwijck; D Liénard; M Beauduin; P Y Dietrich; V Russo; J Kerger; G Masucci; E Jäger; J De Greve; J Atzpodien; F Brasseur; P G Coulie; P van der Bruggen; T Boon
Journal:  Int J Cancer       Date:  1999-01-18       Impact factor: 7.396

3.  Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung.

Authors:  H Echchakir; I Vergnon; G Dorothée; D Grunenwald; S Chouaib; F Mami-Chouaib
Journal:  Int Immunol       Date:  2000-04       Impact factor: 4.823

4.  Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood.

Authors:  P R Dunbar; G S Ogg; J Chen; N Rust; P van der Bruggen; V Cerundolo
Journal:  Curr Biol       Date:  1998-03-26       Impact factor: 10.834

5.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.

Authors:  P P Lee; C Yee; P A Savage; L Fong; D Brockstedt; J S Weber; D Johnson; S Swetter; J Thompson; P D Greenberg; M Roederer; M M Davis
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

6.  The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene.

Authors:  K T Hogan; D P Eisinger; S B Cupp; K J Lekstrom; D D Deacon; J Shabanowitz; D F Hunt; V H Engelhard; C L Slingluff; M M Ross
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

7.  Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.

Authors:  C Yee; P A Savage; P P Lee; M M Davis; P D Greenberg
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

8.  Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival.

Authors:  P Weynants; J Thonnard; M Marchand; M Delos; T Boon; P G Coulie
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

9.  Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients.

Authors:  C Asselin-Paturel; H Echchakir; G Carayol; F Gay; P Opolon; D Grunenwald; S Chouaib; F Mami-Chouaib
Journal:  Int J Cancer       Date:  1998-07-03       Impact factor: 7.396

10.  Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.

Authors:  B Thurner; I Haendle; C Röder; D Dieckmann; P Keikavoussi; H Jonuleit; A Bender; C Maczek; D Schreiner; P von den Driesch; E B Bröcker; R M Steinman; A Enk; E Kämpgen; G Schuler
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

View more
  21 in total

1.  Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy.

Authors:  Salem Chouaib
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 2.  High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors.

Authors:  Martha A Alexander-Miller
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Multiple costimulatory modalities enhance CTL avidity.

Authors:  James W Hodge; Mala Chakraborty; Chie Kudo-Saito; Charlie T Garnett; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

4.  Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.

Authors:  Sixun Yang; Kwong-Yok Tsang; Jeffrey Schlom
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

5.  In vivo modulation of avidity in highly sensitive CD8(+) effector T cells following viral infection.

Authors:  Beth C Holbrook; Rama D Yammani; Lance K Blevins; Martha A Alexander-Miller
Journal:  Viral Immunol       Date:  2013-08-24       Impact factor: 2.257

6.  Lentiviral calnexin-modified dendritic cells promote expansion of high-avidity effector T cells with central memory phenotype.

Authors:  Bei Wang; Shuhong Han; Lily Lien; Lung-Ji Chang
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

7.  Increased sensitivity to antigen in high avidity CD8(+) T cells results from augmented membrane proximal T-cell receptor signal transduction.

Authors:  Sharad K Sharma; Martha A Alexander-Miller
Journal:  Immunology       Date:  2011-04-19       Impact factor: 7.397

8.  Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses.

Authors:  Charles B Kemmler; Eric T Clambey; Ross M Kedl; Jill E Slansky
Journal:  J Immunol       Date:  2011-09-21       Impact factor: 5.422

Review 9.  Current status and recent advances of next generation sequencing techniques in immunological repertoire.

Authors:  X-L Hou; L Wang; Y-L Ding; Q Xie; H-Y Diao
Journal:  Genes Immun       Date:  2016-03-10       Impact factor: 2.676

10.  Proteomic analysis of exosomes secreted by human mesothelioma cells.

Authors:  Joost P J J Hegmans; Martin P L Bard; Annabrita Hemmes; Theo M Luider; Monique J Kleijmeer; Jan-Bas Prins; Laurence Zitvogel; Sjaak A Burgers; Henk C Hoogsteden; Bart N Lambrecht
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.